Drugs that contain Oxybutynin Chloride
1. Ditropan Xl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5840754 | JANSSEN PHARMS | Dosage form comprising oxybutynin |
May, 2015
(8 years ago) | |
| US6262115 | JANSSEN PHARMS | Method for the management of incontinence |
May, 2015
(8 years ago) | |
| US5674895 | JANSSEN PHARMS | Dosage form comprising oxybutynin |
May, 2015
(8 years ago) | |
| US5912268 | JANSSEN PHARMS | Dosage form and method for treating incontinence |
May, 2015
(8 years ago) | |
|
US5912268 (Pediatric) | JANSSEN PHARMS | Dosage form and method for treating incontinence |
Nov, 2015
(8 years ago) | |
|
US6262115 (Pediatric) | JANSSEN PHARMS | Method for the management of incontinence |
Nov, 2015
(8 years ago) | |
|
US5840754 (Pediatric) | JANSSEN PHARMS | Dosage form comprising oxybutynin |
Nov, 2015
(8 years ago) | |
|
US5674895 (Pediatric) | JANSSEN PHARMS | Dosage form comprising oxybutynin |
Nov, 2015
(8 years ago) | |
Market Authorisation Date: 16 December, 1998
Treatment: Management of incontinence, mgt of hormone replacement therapy, treatment of involuntary incontinence, mgt overactive bladder and increasing compliance in such pt
Dosage: TABLET, EXTENDED RELEASE;ORAL
DITROPAN XL family patents
2. Gelnique patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272061 | ABBVIE | Compositions and methods for unoccluded transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7179483 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US8241662 | ABBVIE | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7029694 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US10449173 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(5 years from now) | |
| US9259388 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(5 years from now) | |
| US8920392 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 27, 2012 |
Market Authorisation Date: 27 January, 2009
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence; Treatment of patients with an overactive bladder with symptoms of urinary frequency, ...
Dosage: GEL;TRANSDERMAL
GELNIQUE family patents